Adaptive Biotechnologies Corp (ADPT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through two operating segments: Minimal Residual Disease (MRD), focused on the clonoSEQ diagnostic test, and Immune Medicine, focused on drug discovery and collaboration (notably with Genentech). The company operates as a large accelerated filer.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $43.2 million | $48.9 million | $85.1 million | $86.6 million |
| Net Loss (GAAP) | $(46.2) million | $(47.8) million | $(93.7) million | $(105.5) million |
| Net Loss Per Share | $(0.31) | $(0.33) | $(0.64) | $(0.73) |
| Adjusted EBITDA | $(21.4) million | $(24.8) million | $(49.6) million | $(61.9) million |
| Cash & Marketable Securities | $291.9 million (as of June 30, 2024) | $346.4 million (as of Dec 31, 2023) | ||
| Operating Cash Flow (YTD) | $(55.7) million | $(82.7) million | N/A |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue declined 12% QoQ and 2% YTD. This was driven by a 36% increase in MRD revenue (to $35.3M) due to higher clinical test volume and $3.0M in regulatory milestone revenue. Conversely, Immune Medicine revenue fell 66% (to $7.9M) primarily due to a $15.8M decrease in collaboration revenue from the Genentech agreement.
- Restructuring and Impairment: The company recognized a $7.2 million impairment charge in Q2 2024 related to vacating leased space in South San Francisco and halting certain software enhancements. Total restructuring costs for the six months ended June 30, 2024, were $8.9 million.
- Expense Reduction: Operating expenses decreased due to reduced headcount and lower R&D investments in drug discovery. R&D expenses dropped 21% QoQ and 14% YTD.
- Segment Performance: MRD Adjusted EBITDA deficit improved by $11.8M QoQ, while Immune Medicine Adjusted EBITDA deficit widened by $8.3M QoQ due to the revenue drop from the Genentech collaboration.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($291.9M) are sufficient to fund operations for at least the next 12 months. The company has a Revenue Interest Purchase Agreement with OrbiMed allowing for up to $125M in additional funding installments by September 2025.
- Outlook: MRD revenue is expected to increase long-term as clinical testing volume grows. Immune Medicine revenue is expected to decrease in the short term due to the winding down of upfront revenue recognition from the Genentech agreement but is expected to increase long-term as therapies advance.
- Risks: Key risks include reliance on the Genentech collaboration, the novelty of immune medicine, regulatory approval uncertainties for customer therapeutics (which trigger milestone payments), and the need for additional capital if cash burn exceeds projections.
Investor Verification Checklist
- Genentech Revenue Trajectory: Verify the sustainability of Immune Medicine revenue given the significant drop in collaboration revenue and the timeline for future milestone triggers.
- Restructuring Impact: Confirm that the $7.2M impairment and $8.9M total restructuring costs are one-time events and assess the long-term benefit of the cost reductions.
- MRD Growth Drivers: Validate the 36% increase in clonoSEQ test volume and the sustainability of the $3.0M regulatory milestone revenue recognized in Q2.
- Cash Burn Rate: Monitor the net cash used in operating activities ($55.7M YTD) against the $291.9M cash balance to ensure the 12-month runway remains accurate.
- Revenue Interest Liability: Review the $132.1M revenue interest liability and the effective interest rate (8.2%) to understand future cash outflow obligations tied to revenue performance.